Capricor Therapeutics
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | <1m | <1m | 2.6m | 25.2m | 18.8m | 48.5m | 77.2m |
| % growth | (69 %) | (21 %) | 942 % | 887 % | (26 %) | 159 % | 59 % |
| EBITDA | (13.7m) | (21.3m) | (30.2m) | (24.7m) | (29.8m) | (46.3m) | (39.1m) |
| % EBITDA margin | (4423 %) | (8700 %) | (1183 %) | (98 %) | (159 %) | (95 %) | (51 %) |
| Profit | (13.7m) | (20.0m) | (29.0m) | (22.3m) | (42.9m) | (30.2m) | (11.4m) |
| % profit margin | (4402 %) | (8176 %) | (1137 %) | (89 %) | (229 %) | (62 %) | (15 %) |
| EV / revenue | 226.0x | 288.9x | 37.4x | 6.0x | 7.9x | 3.1x | 1.9x |
| EV / EBITDA | -5.1x | -3.3x | -3.2x | -6.1x | -5.0x | -3.2x | -3.8x |
| R&D budget | 8.5m | 13.6m | 21.8m | 36.4m | - | - | - |
| R&D % of revenue | 2726 % | 5542 % | 855 % | 145 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
| N/A | N/A | IPO | |
$3.4m | Post IPO Equity | ||
| N/A | $2.8m | Debt | |
$2.0m | Post IPO Equity | ||
| N/A | $6.0m | Debt | |
| N/A | $26.0m | Post IPO Equity | |
| N/A | $10.0m | Post IPO Equity | |
$3.4m | Grant | ||
$4.2m | Grant | ||
| N/A | $3.7m | Post IPO Equity | |
| N/A | $5.1m | Post IPO Equity | |
* | N/A | $23.0m | Post IPO Equity |
| Total Funding | €6.9m | ||
Related Content
Recent News about Capricor Therapeutics
EditCapricor Therapeutics, Inc. (Nasdaq: CAPR) is a clinical-stage biotechnology company that focuses on developing innovative treatments for serious diseases. The company specializes in cell and exosome-based therapeutics, which are advanced medical treatments derived from cells and tiny particles that cells release. These therapeutics are designed to treat and prevent various diseases, including heart disease, Duchenne Muscular Dystrophy, and complications related to COVID-19.
Capricor operates in the biotechnology and pharmaceutical market, targeting both healthcare providers and patients who suffer from severe and often life-threatening conditions. The company’s business model revolves around the discovery, development, and commercialization of its unique therapeutic products. This means they invest heavily in research and clinical trials to prove the effectiveness and safety of their treatments before bringing them to market.
Revenue generation for Capricor primarily comes from the successful commercialization of their therapeutic products. This includes selling their treatments to hospitals, clinics, and other healthcare facilities. Additionally, they may receive funding through partnerships, grants, and collaborations with other organizations in the healthcare sector.
Capricor is committed to advancing medical science and improving patient outcomes. They offer a dynamic work environment that values diversity, flexibility, and growth, making it an attractive place for talented individuals looking to make a significant impact in the field of biotechnology.
Keywords: biotechnology, cell-based therapeutics, exosome-based therapeutics, heart disease, Duchenne Muscular Dystrophy, COVID-19, clinical trials, healthcare innovation, Nasdaq CAPR, medical research.